scholarly journals Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

2021 ◽  
Author(s):  
Boyu Qin ◽  
Lingli Xin ◽  
Qingxiang Hou ◽  
Bo Yang ◽  
Jing Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Survival Benefit ◽  
Progression Free Survival ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Free Survival ◽  
Lung Cancer Patients ◽  
First Line Treatment

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

2017 ◽  
Vol 35 (12) ◽  
pp. 1281-1287 ◽  
Author(s):  
Marcello Tiseo ◽  
Luca Boni ◽  
Francesca Ambrosio ◽  
Andrea Camerini ◽  
Editta Baldini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Progression Free Survival ◽  
Small Cell ◽  
Phase Iii ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Extensive Disease ◽  
Free Survival ◽  
First Line Treatment

Purpose Considering promising results in phase II studies, a randomized phase III trial was designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide for treatment of extensive-disease (ED) small-cell lung cancer (SCLC). Patients and Methods Treatment-naive patients with ED-SCLC were randomly assigned to receive either cisplatin plus etoposide (arm A) or the same regimen with bevacizumab (arm B) for a maximum of six courses. In the absence of progression, patients in arm B continued bevacizumab alone until disease progression or for a maximum of 18 courses. The primary end point was overall survival (OS). Results Two hundred four patients were randomly assigned and considered in intent-to-treat analyses (103 patients in arm A and 101 patients in arm B). At a median follow-up of 34.9 months in arm A and arm B, median OS times were 8.9 and 9.8 months, and 1-year survival rates were 25% and 37% (hazard ratio, 0.78; 95% CI, 0.58 to 1.06; P = .113), respectively. A statistically significant effect of bevacizumab on OS in patients who received maintenance was seen (hazard ratio, 0.60; 95% CI, 0.40 to 0.91; P = .011). Median progression-free survival times were 5.7 and 6.7 months in arm A and arm B, respectively ( P = .030). Regarding hematologic toxicity, no statistically significant differences were observed; for nonhematologic toxicity, only hypertension was more frequent in arm B (grade 3 or 4, 1.0% v 6.3% in arms A v B, respectively; P = .057). Conclusion The addition of bevacizumab to cisplatin and etoposide in the first-line treatment of ED-SCLC had an acceptable toxicity profile and led to a statistically significant improvement in progression-free survival, which, however, did not translate into a statistically significant increase in OS. Further research with novel antiangiogenic agents, particularly in the maintenance setting, is warranted.

Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment

Oncology ◽  
2005 ◽  
Vol 68 (4-6) ◽  
pp. 350-355 ◽  
Author(s):  
Chih-Hsin Yang ◽  
Min-Chun Chen ◽  
Ann-Lii Cheng ◽  
Chih-Hung Hsu ◽  
Kun-Huei Yeh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Survival Outcome ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
Conventional Dose ◽  
First Line Treatment

scholarly journals Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases

2016 ◽  
Vol 12 (6) ◽  
pp. 4635-4642 ◽  
Author(s):  
Dimitra Stefanou ◽  
Sofia Stamatopoulou ◽  
Antigoni Sakellaropoulou ◽  
Gavriil Akakios ◽  
Marina Gkiaouraki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document